Sabitlenmiş Tweet
Sanaz Soltani, MD
643 posts
Sanaz Soltani, MD
@SoltaniMD
Heme/Onc🩸🧪🥼 | Training:@NCICCR_WMB @NIH_NHLBI @GeisingerHealth | Currently:@WVUcancer | Posts=mine≠employer/endorsement | #HOWPG #Wolfpack #OncTwitter
Katılım Haziran 2013
386 Takip Edilen300 Takipçiler
Cool
David Steensma, MD@DavidSteensma
#HematologyTweetstory 32: lymph nodes with names. There’s also a major personal announcement in this thread. We each have lots of lymph nodes: an estimated 500-600 (Image: @MayoClinic). Like stars, they cluster. (Did you ever think of your axilla as a lymphatic “galaxy”?)🙂/1
English
Sanaz Soltani, MD retweetledi
#ASCO22 is only 2 weeks away! Below are my Top 10 abstracts I'm looking forward to in #bcsm across early & metastatic settings.
I've also attached the "why" - what is intriguing me about these particular abstracts or why they are important IMO.
@SarahCannonDocs @OncoAlert
English
Sanaz Soltani, MD retweetledi
APHINITY: Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive #breastcancer
"Age per se is not a reason either to prescribe more aggressive therapies or to expect a different treatment benefit" ~IDFS for age ≤40 or >40
@JNCI_Now @OncoAlert
academic.oup.com/jnci/advance-a…
English
3rd night in a row of getting the kiddos fed and to bed by myself since hubs is working the 2-11 shift. I may be way behind on my work, but my kids are clean, fed and asleep🤷♀️. I will catch up someday #workingmom #parenting #WomenInMedicine #womeninstem #medtwitter
GIF
English
Sanaz Soltani, MD retweetledi
Great talk by my colleague and co-mentor @RoschewskiMD from @NCICCR_Lymphoma on a novel trial with Acala window in 1L DLBCL. Responses to BTKi across all COO and LymphGEN subtypes with ctDNA showing an early indicator of radiographic response #ASH21 #lymphoma
English
Sanaz Soltani, MD retweetledi
EBCTCG analysis of taxane with and w/o anthracycline. 15% relative reduction and 2.5% absolute reduction in invasive recurrence for A+T vs T. Larger reduction with concurrent schedules.
@OncoAlert #SABCS2021 #bcsm
English
Sanaz Soltani, MD retweetledi
Breaking news: Triplet therapy with Darolutamide + Docetaxel + ADT improves OS compared to docetaxel + ADT in men with mCSPC #ProstateCancer👉Significantly improved OS, the primary endpoint. Another position triplet Rx trial after Peace-1. @OncoAlert @urotoday
Axel S. Merseburger@amerseburger
Exciting news #ARASENS #mHSPC pos. primary endpoint for OS, safety similar 🦾 - looking forward see presentation 👏#GU22 @OncoAlert @uroupdate @Uroweb @myESMO @AzadOncology @neerajaiims @scserendipity1 @DrChoueiri @APCCC_Lugano media.bayer.com/baynews/baynew…
English
Sanaz Soltani, MD retweetledi
👉"I think FES-PET/CT may change patient management for initial staging of ER+ #lobular #breastcancer"👈 Early results look promising! Thx Dr. Covington @huntsmancancer
#bcsm @ASTRO_org @ASCO @RadiologyACR @radiology_rsna @AuntMinnie
auntminnie.com/index.aspx?sec…
English
Sanaz Soltani, MD retweetledi
I’ve never seen a better graphical depiction of grief
English
Sanaz Soltani, MD retweetledi
Free Self Paced on-line @NIH #Pharmacology course
#pharmacology is very complicated, but necessary for many aspects of #medicine & #research
Learn from a course directed by 2 of the best: Drs. Cordes & Figg @WilliamFigg1
#MedTwitter
Link: ocr.od.nih.gov/courses/princi…
English
Sanaz Soltani, MD retweetledi
#SABCS21 Abstracts are out! Here’s what I’m looking forward too!
@matteolambe @OncoAlert @ErikaHamilton9 @JavierCortesMD @SABCSSanAntonio @DrLoveResearch @BrownUCancer
English
@Dr_RShatsky I just bombarded your inbox but if I could like your comments a million times I would. Unless you’ve lived it, you don’t get it. I bit my tongue many times when it came up. Luckily I have worked in very supportive environments
English
Breastfeeding as a full time working mom is hard. It takes an enormous amount of time to maintain and is really underappreciated by all but other breastfeeding moms. I literally lose money by doing it. Shout out to those trying to make it work #breastfeeding #workingmom #Pumping
English
Caught up on:
Clinic notes
Emails
Slides/LOI submission
Manuscript reviews
Grant reviews
Peer to peer reviews
Suddenly have time for writing manuscripts ?!!
It feels surreal
#AcademicTwitter
English
Sanaz Soltani, MD retweetledi
Very happy to see the FDA approval of adjuvant atezolizumab in patients with resected PD-L1+ early stage NSCLC. So excited to have been a part of the practice changing IMpower010 trial! Making a difference in the lives of NSCLC patients! #LCSM
English
Sanaz Soltani, MD retweetledi
FDA Approves Adjuvant Atezolizumab for PD-L1+ Non–Small Cell Lung Cancer @TargetedOnc targetedonc.com/view/fda-appro…
English
Sanaz Soltani, MD retweetledi
Abemaciclib + endocrine therapy for early breast cancer was approved by @FDAOncology based on the monarchE study.
Results of the the primary outcome analysis presented at the #ESMOVirtualPlenary are available #openaccess in @Annals_Oncology annalsofoncology.org/article/S0923-… #bcsm
English
Sanaz Soltani, MD retweetledi
Updated data from #monarchE trial just presented at #ESMOVirtualPlenary showing increased magnitude of benefit for the addition of #abemaciclib to adjuvant #EndocrineTherapy in high-risk HR+/HER2- #BreastCancer patients: very important data!
@myESMO @OncoAlert @Annals_Oncology
English
Sanaz Soltani, MD retweetledi
Who are the patients who will benefit the most from abemaciclib in adjuvant ET? What is the optimum duration for CDK 4/6 inhibitors? @dradityabardia @matteolambe @kevinpunie @myESMO @prat_aleix
English